Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multisite Phase Ib Study of Pevonedistat, Azacitidine (or Decitabine), and Venetoclax (PAVE) for the Treatment of Patients With Acute Myelogenous Leukemia (AML)

NCT04172844 is registered in ClinicalTrials.gov with Medical College of Wisconsin as lead sponsor.

NCT NCT04172844
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04172844 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multisite Phase Ib Study of Pevonedistat, Azacitidine (or Decitabine), and Venetoclax (PAVE) for the Treatment of Patients With Acute Myelogenous Leukemia (AML)
Lead sponsor
Medical College of Wisconsin
Phase
Phase 1
Overall status
Terminated
Start date
January 13, 2020
Completion date
February 27, 2022
Enrollment
16 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelogenous leukemia